BioNeutral Group, Inc. (BONU)
BioNeutral Group, Inc. is a specialty technology-based life science company. They have developed a technology platform that neutralizes harmful environmental contaminants, toxins, and dangerous microorganisms. These include bacteria, viruses, mold, fungi, and spores. BioNeutral has their headquarters in Morristown, New Jersey, with lab facilities at the New Jersey Institute of Technology in Newark.
BioNeutral has pioneered the use of Combinational Chemistry to create the world's most advanced products for infection control, eradication of hospital-acquired infections (HAIs), and eradication of noxious odors, stains, and toxic gases. Combinational Chemistry is the science of combining well-proven components into new formulas and compounds for an exponential increase in effectiveness, efficiency, and safety over the use of the individual components.
BioNeutral Group's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a significant increase in speed and power. The company's proprietary platform technology has been proven effective in surface, water, and airborne applications. Their antimicrobial line of products under the Ygiene® brand has received approval from the EPA for sale in the U.S. The product line has also received approval for sale in Germany and is permitted to be sold in the United Kingdom, France, and Sweden.
BioNeutral Group and Barnabas Health in West Orange, New Jersey, recently announced a collaborative research and revenue sharing agreement. The parties will develop protocols to trial Ygiene 206, a detergent cleaner, 90-second disinfectant, and 20-minute sterilant. Moreover, they will test new formulations designed for rapid cleaning and sterilization of surgical instruments, scopes, fabric and skin at Barnabas Health facilities. Barnabas Health is the largest nonprofit integrated health care delivery system in New Jersey and one of the largest in the nation.
Ohr Pharmaceutical, Inc. (OHRP)
Ohr Pharmaceutical, Inc. is a pharmaceutical company with corporate headquarters in New York, New York. The company's dedication is to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. Ohr Pharmaceutical is currently focusing on two lead compounds. One is Squalamine eye drops for the treatment of the wet form of age-related macular degeneration. The other is OHR/AVR118 for the treatment of cancer cachexia, currently undergoing investigation in a Phase II trial.
The company's Squalamine is a first-in-class systemic intracellular anti-angiogenic drug with a novel mechanism of action. Its ophthalmic formulation has undergone evaluation against the wet form of age-related macular degeneration. In Phase II trials, in which no drug-related ocular or systemic effects were observed, stabilization or improvement in visual activity was documented in the vast majority of patients, with both early and advanced lesions responding.
The company's OHR/AVR118 is a broad-spectrum peptide nucleic acid (PNA) immunomodulator drug. It is available in a preservative-free formulation that is stable at room temperature. The drug is currently undergoing evaluation in a Phase IIb clinical study for Cancer Cachexia at a leading Cancer Centre in Canada. Cancer Cachexia is a severe wasting disorder characterized by weight loss, muscle atrophy, fatigue, weakness, and significant loss of appetite. This disorder is often seen in late stage Cancer patients.
In recent news, Ohr Pharmaceutical announced that they were awarded Unites States (#8,084,039) and European (EP1399108) patents titled "Preparation of a Therapeutic Composition." Significantly strengthening the company's cancer cachexia program, the patents include claims related to the chemical structures, sequences of the peptide constituents, and method of manufacture of OHR/AVR118.
Rackwise, Inc. engages in software development and marketing within the growing markets for IT infrastructure, data center monitoring, management and optimization, data center cost efficiency, and green data centers. More than 150 companies use the company's flagship Data Center Infrastructure Management (DCiM) product, RACKWISE®, for tracking, managing, planning, optimizing, and providing cost analysis of IT infrastructure.
The company delivers IT infrastructure data center analytics and intelligence that enable Executive and Data Center Management to track and optimize asset utilization, monitor and adjust power and energy usage for cost savings, and control overall and LOB IT costs. It also enables them to plan for future growth and/or consolidation with impact analysis, measure progress towards achieving Green data center initiatives, and ensure business continuity.
RACKWISE® is a multi-layered software product that provides a series of solutions for managing multiple dimensions of an enterprise's IT infrastructure and data center(s). Using Rackwise allows companies to optimize their use of components, including power, cooling, space, servers, networks, cables, and more. Rackwise delivers four solution areas: Data Center Essentials, Data Center Optimization, Data Center Intelligence, and Data Center Business.
Rackwise recently announced that they will release version 3.6 of their core DCiM™ software product, the Rackwise® Data Center Manager (DCM), in April of 2012. Pursuant to the terms of the company's recently executed multi-year software integration and license agreement with Intel Corp. announced during the fourth quarter of 2011, the Rackwise® DCM version 3.6 product will be marketed by both Rackwise and Intel globally, with initial emphasis on the Asia-Pacific and European markets.